The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Background and Aims Activation of the antitumor immune response using programmed
death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with …

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for
Hepatocellular Carcinoma Page 1 1 International Liver Cancer Association (ILCA) White Paper …

The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent
advances in genomics have increased our understanding of the mechanisms by which …

Recent years have seen significant progress in the systemic treatment of hepatocellular
carcinoma (HCC), including the advent of immunotherapy. While several large phase III …

Hypoxia is a persistent physiological feature of many different solid tumors and a key driver
of malignancy, and in recent years, it has been recognized as an important target for cancer …

Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer in the
world. Recently, the effectiveness of new antiviral therapies and the HBV vaccine have …